PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
118.09%
Revenue growth above 1.5x 5715.T's 11.26%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
134.81%
Gross profit growth above 1.5x 5715.T's 18.76%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
2047.84%
EBIT growth above 1.5x 5715.T's 146.23%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
810.34%
Operating income growth above 1.5x 5715.T's 67.99%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
929.47%
Net income growth above 1.5x 5715.T's 177.21%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
928.95%
EPS growth above 1.5x 5715.T's 177.25%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
928.95%
Diluted EPS growth above 1.5x 5715.T's 177.25%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.71%
10Y revenue/share CAGR above 1.5x 5715.T's 4.76%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
56.91%
5Y revenue/share CAGR above 1.5x 5715.T's 16.59%. David Dodd would look for consistent product or market expansions fueling outperformance.
-35.67%
Negative 3Y CAGR while 5715.T stands at 1.88%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-100.00%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.14%
Below 50% of 5715.T's 319.45%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
87.56%
5Y net income/share CAGR above 1.5x 5715.T's 38.02%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-9.54%
Negative 3Y CAGR while 5715.T is 301.40%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
294.34%
10Y equity/share CAGR above 1.5x 5715.T's 106.79%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
56.00%
5Y equity/share CAGR 1.25-1.5x 5715.T's 42.79%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
14.07%
3Y equity/share CAGR 1.25-1.5x 5715.T's 11.62%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
46.41%
AR growth well above 5715.T's 2.31%. Michael Burry fears inflated revenue or higher default risk in the near future.
-31.45%
Inventory is declining while 5715.T stands at 5.52%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-5.08%
Negative asset growth while 5715.T invests at 2.10%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
11.77%
1.25-1.5x 5715.T's 8.96%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-15.10%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-5.64%
Our R&D shrinks while 5715.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-23.73%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.